$-3.42 EPS Expected for Intercept Pharmaceuticals, Inc. (ICPT); 3 Bullish Analysts Covering IAMGOLD (TSE:IMG)

April 18, 2018 - By Kurt Siggers

IAMGOLD Corporation (TSE:IMG) Logo

Among 7 analysts covering Iamgold Corp (TSE:IMG), 3 have Buy rating, 3 Sell and 1 Hold. Therefore 43% are positive. Iamgold Corp had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating given on Tuesday, December 20 by Scotia Capital. The company was downgraded on Friday, September 29 by Canaccord Genuity. The firm earned “Buy” rating on Monday, December 11 by Desjardins Securities. As per Thursday, August 24, the company rating was maintained by BMO Capital Markets. The firm has “Buy” rating given on Tuesday, November 8 by TD Securities. On Tuesday, January 17 the stock rating was maintained by Scotia Capital with “Underperform”. The firm has “Sector Perform” rating by Scotia Capital given on Tuesday, November 8. The firm earned “Sell” rating on Friday, February 19 by Mackie. RBC Capital Markets maintained IAMGOLD Corporation (TSE:IMG) rating on Friday, January 29. RBC Capital Markets has “Underperform” rating and $2.45 target. BMO Capital Markets maintained IAMGOLD Corporation (TSE:IMG) on Wednesday, June 7 with “Market Perform” rating. See IAMGOLD Corporation (TSE:IMG) latest ratings:

11/12/2017 Broker: Desjardins Securities Rating: Buy Maintain
20/10/2017 Broker: Canaccord Genuity Rating: Old Target: $9.50 New Target: $8.75 Target Down

Analysts expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report $-3.42 EPS on May, 3.They anticipate $0.19 EPS change or 5.26% from last quarter’s $-3.61 EPS. After having $-4.43 EPS previously, Intercept Pharmaceuticals, Inc.’s analysts see -22.80% EPS growth. The stock increased 0.08% or $0.06 during the last trading session, reaching $73.85. About 239,097 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 18, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $2.17 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.02, from 1.33 in 2017Q3. It is negative, as 19 investors sold Intercept Pharmaceuticals, Inc. shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. Employees Retirement Systems Of Ohio owns 7,155 shares for 0% of their portfolio. Natixis has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Proshare Advisors Ltd holds 0.01% or 14,004 shares. Pacad Inv reported 2,400 shares. Old Second Bancshares Of Aurora accumulated 200 shares. State Of Alaska Department Of Revenue holds 0% or 1,600 shares. Voloridge Investment Llc reported 16,424 shares. Raymond James & Assoc accumulated 0% or 34,073 shares. Columbia Wanger Asset Mngmt Limited Company invested in 117,425 shares or 0.1% of the stock. Earnest Prtnrs Ltd Liability holds 2 shares or 0% of its portfolio. Public Employees Retirement Association Of Colorado reported 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Edge Wealth Mngmt Limited Co accumulated 750 shares. Atlantic Group Limited Liability Corporation reported 275 shares. Dsc Advsrs L P has 3,500 shares for 0.12% of their portfolio. 38,500 are owned by Rhenman And Ptnrs Asset Management.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 74 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Buy” rating given on Monday, September 25 by Credit Suisse. As per Thursday, June 1, the company rating was maintained by Credit Suisse. The firm has “Strong-Buy” rating given on Tuesday, September 22 by Vetr. The firm has “Neutral” rating given on Friday, September 22 by Citigroup. The rating was maintained by Cowen & Co on Friday, September 22 with “Buy”. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Hold” rating by Needham on Friday, January 20. Vetr upgraded it to “Strong-Buy” rating and $207.80 target in Thursday, September 17 report. Wedbush maintained the stock with “Buy” rating in Thursday, February 1 report. The firm has “Outperform” rating by Wedbush given on Friday, December 30. The rating was maintained by Bank of America with “Underperform” on Friday, October 13.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>